Spero Therapeutics (SPRO) Receives a Buy from Cowen & Co.

By Jason Carr

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Spero Therapeutics (SPROResearch Report). The company’s shares closed last Monday at $10.71.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 22.0% and a 47.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spero Therapeutics with a $28.67 average price target, a 163.3% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.48 and a one-year low of $5.52. Currently, Spero Therapeutics has an average volume of 37.46K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.